The stock of Soleno Therapeutics Inc (NASDAQ: SLNO) has decreased by -0.99 when compared to last closing price of 52.70.Despite this, the company has seen a loss of -2.47% in its stock price over the last five trading days. seekingalpha.com reported 2024-10-10 that Soleno Therapeutics’ DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR’s unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO’s market prospects.
Is It Worth Investing in Soleno Therapeutics Inc (NASDAQ: SLNO) Right Now?
Additionally, the 36-month beta value for SLNO is -1.44. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SLNO is 27.68M and currently, short sellers hold a 17.93% ratio of that float. The average trading volume of SLNO on October 24, 2024 was 598.11K shares.
SLNO’s Market Performance
SLNO stock saw an increase of -2.47% in the past week, with a monthly gain of 6.97% and a quarterly increase of 7.63%. The volatility ratio for the week is 2.92%, and the volatility levels for the last 30 days are 4.12% for Soleno Therapeutics Inc (SLNO). The simple moving average for the past 20 days is 0.72% for SLNO’s stock, with a 13.44% simple moving average for the past 200 days.
Analysts’ Opinion of SLNO
Many brokerage firms have already submitted their reports for SLNO stocks, with H.C. Wainwright repeating the rating for SLNO by listing it as a “Buy.” The predicted price for SLNO in the upcoming period, according to H.C. Wainwright is $70 based on the research report published on September 03, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see SLNO reach a price target of $72. The rating they have provided for SLNO stocks is “Outperform” according to the report published on May 10th, 2024.
Piper Sandler gave a rating of “Overweight” to SLNO, setting the target price at $93 in the report published on February 05th of the current year.
SLNO Trading at 3.47% from the 50-Day Moving Average
After a stumble in the market that brought SLNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.15% of loss for the given period.
Volatility was left at 4.12%, however, over the last 30 days, the volatility rate increased by 2.92%, as shares surge +7.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.06% upper at present.
During the last 5 trading sessions, SLNO fell by -2.19%, which changed the moving average for the period of 200-days by +25.28% in comparison to the 20-day moving average, which settled at $51.82. In addition, Soleno Therapeutics Inc saw 29.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLNO starting from Abingworth Bioventures VII LP, who proposed sale 949,336 shares at the price of $54.16 back on Oct 21 ’24. After this action, Abingworth Bioventures VII LP now owns shares of Soleno Therapeutics Inc, valued at $51,416,038 using the latest closing price.
Abingworth Bioventures VII LP, the Rule 144 Affiliate of Soleno Therapeutics Inc, proposed sale 2,522,751 shares at $49.63 during a trade that took place back on Oct 07 ’24, which means that Abingworth Bioventures VII LP is holding shares at $125,204,132 based on the most recent closing price.
Stock Fundamentals for SLNO
Current profitability levels for the company are sitting at:
- -19.83 for the present operating margin
- 0.41 for the gross margin
The net margin for Soleno Therapeutics Inc stands at -18.98. The total capital return value is set at -0.23. Equity return is now at value -44.62, with -39.04 for asset returns.
Based on Soleno Therapeutics Inc (SLNO), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -144.68. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -604.59.
Currently, EBITDA for the company is -36.71 million with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 571.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.24.
Conclusion
In conclusion, Soleno Therapeutics Inc (SLNO) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
